BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)
BTIG reaffirmed a Buy rating on Praxis Precision Medicines (PRAX) and cut its price target to $810 from $843 on June 2. The firm cited Phase 2/3 POWER1 results for vormatrigine, noting revenue loss but pointing to continued patient retention in an open-label extension and response/seizure trends. Truist also maintained a Buy rating, raising its target to $715.
How this was made
The 30-second read
Why it matters
For PRAX, the key new datapoint is BTIG’s price target reduction while keeping a Buy rating, anchored to specific POWER1 trial observations (open-label extension movement, response indicator, seizure diminution, and low event-related withdrawals).
Market read
This is an analyst note with a concrete PT change and a clinical-trial metric recap that can influence short-term sentiment and positioning in PRAX.
What to watch
The article emphasizes hope for recovery but provides limited detail on regulatory/next-step milestones; traders may need confirmation of how the 30 mg dose and response translate into future endpoints.
Background
The piece summarizes BTIG’s June 2 analyst action on Praxis following POWER1 (vormatrigine) Phase 2/3 results, plus a prior Truist PT increase from May 13.
Ticker impact
BTIG reaffirmed a Buy on Praxis Precision Medicines and cut its price target, citing POWER1 vormatrigine Phase 2/3 trial revenue loss but potential recovery.
Likely modest downside/volatility risk from the PT reduction, offset by the maintained Buy and discussion of response/extension dynamics.
The article’s actionable change is the PT reduction ($843→$810) while the thesis remains constructive due to open-label extension retention and response indicators meeting criteria.
Market effects
Reinforces that CNS/epilepsy biotech read-through can remain constructive even when trial economics (revenue loss) worsen, depending on extension/response metrics.
No specific regional impact described.
No explicit global market linkage beyond general biotech trial interpretation.
Counterpoint
The PT cut despite a maintained Buy may signal the market is still discounting the POWER1 program’s commercial trajectory; extension success may not fully de-risk efficacy/label outcomes.
Key entities
- companyPraxis Precision Medicines
NASDAQ-listed biotech developing CNS therapies; subject of BTIG’s Buy/PT action and POWER1 trial discussion.
- analyst_firmBTIG
Reaffirmed Buy and reduced PRAX price target on June 2, citing POWER1 trial dynamics and recovery hope.
- analyst_firmTruist Financial
Previously increased PRAX price target (May 13) and highlighted upcoming value-inflecting events.
